DASHENLIN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.2 CNY | +2.27% |
|
-5.02% | -14.86% |
| 03-18 | Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares | MT |
| 03-05 | Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15,944 | 27,171 | 51,603 | 33,307 | 37,585 | 24,144 | 24,144 | - |
| Enterprise Value (EV) 1 | 15,944 | 25,784 | 49,252 | 32,838 | 36,233 | 22,776 | 22,422 | 21,960 |
| P/E ratio | 30 x | 41.5 x | 48.4 x | 42.1 x | 36.3 x | 18.4 x | 15 x | 12.3 x |
| Yield | 1.51% | 1.15% | 1.02% | 1.19% | 1.52% | 2.73% | 3.3% | 3.91% |
| Capitalization / Revenue | 1.8 x | 2.44 x | 3.54 x | 1.99 x | 1.77 x | 0.98 x | 0.79 x | 0.65 x |
| EV / Revenue | 1.8 x | 2.31 x | 3.38 x | 1.96 x | 1.71 x | 0.92 x | 0.73 x | 0.59 x |
| EV / EBITDA | 16.7 x | 21.3 x | 27.5 x | 13.6 x | 19.2 x | 8.99 x | 7.41 x | 6.16 x |
| EV / FCF | - | 21.2 x | 42 x | 117 x | 13.1 x | 8.49 x | 10.2 x | 8.43 x |
| FCF Yield | - | 4.71% | 2.38% | 0.86% | 7.61% | 11.8% | 9.85% | 11.9% |
| Price to Book | 5.24 x | 6.65 x | 9.93 x | 6.3 x | 6.24 x | 3.48 x | 2.99 x | 2.61 x |
| Nbr of stocks (in thousands) | 1,078,303 | 1,078,303 | 1,138,102 | 1,138,968 | 1,138,947 | 1,138,846 | 1,138,846 | - |
| Reference price 2 | 14.79 | 25.20 | 45.34 | 29.24 | 33.00 | 21.20 | 21.20 | 21.20 |
| Announcement Date | 19-03-04 | 20-04-28 | 21-04-19 | 22-04-27 | 23-04-27 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,859 | 11,141 | 14,583 | 16,759 | 21,248 | 24,720 | 30,582 | 37,311 |
| EBITDA 1 | 956 | 1,211 | 1,788 | 2,408 | 1,883 | 2,532 | 3,026 | 3,563 |
| EBIT 1 | 718.3 | 918.3 | 1,448 | 1,041 | 1,421 | 1,868 | 2,293 | 2,779 |
| Operating Margin | 8.11% | 8.24% | 9.93% | 6.21% | 6.69% | 7.56% | 7.5% | 7.45% |
| Earnings before Tax (EBT) 1 | 719.6 | 919.5 | 1,446 | 1,044 | 1,415 | 1,807 | 2,237 | 2,712 |
| Net income 1 | 531.6 | 702.7 | 1,062 | 791.2 | 1,036 | 1,303 | 1,627 | 1,975 |
| Net margin | 6% | 6.31% | 7.28% | 4.72% | 4.87% | 5.27% | 5.32% | 5.29% |
| EPS 2 | 0.4934 | 0.6076 | 0.9375 | 0.6944 | 0.9083 | 1.152 | 1.414 | 1.717 |
| Free Cash Flow 1 | - | 1,214 | 1,174 | 281.7 | 2,759 | 2,683 | 2,208 | 2,606 |
| FCF margin | - | 10.9% | 8.05% | 1.68% | 12.99% | 10.85% | 7.22% | 6.99% |
| FCF Conversion (EBITDA) | - | 100.27% | 65.67% | 11.7% | 146.56% | 105.96% | 72.99% | 73.16% |
| FCF Conversion (Net income) | - | 172.76% | 110.52% | 35.6% | 266.4% | 205.83% | 135.78% | 131.96% |
| Dividend per Share 2 | 0.2226 | 0.2894 | 0.4630 | 0.3472 | 0.5000 | 0.5788 | 0.6989 | 0.8288 |
| Announcement Date | 19-03-04 | 20-04-28 | 21-04-19 | 22-04-27 | 23-04-27 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,996 | 4,301 | 4,404 | 4,677 | 5,044 | 5,097 | 6,430 | 5,947 | 6,045 | 5,731 | 6,760 | 6,842 | 7,121 | 7,384 | 8,553 |
| EBITDA 1 | 385.2 | 300.5 | - | 614 | 498.6 | 426.9 | - | - | - | - | 546.7 | 929.6 | 976.8 | 976.8 | 1,024 |
| EBIT 1 | 400.8 | 224.4 | -41.44 | 492.4 | 438.9 | 291.9 | 197.6 | 684.1 | 576.8 | 371.6 | 181.5 | 540.5 | 553.6 | 580.6 | 637.3 |
| Operating Margin | 10.03% | 5.22% | -0.94% | 10.53% | 8.7% | 5.73% | 3.07% | 11.5% | 9.54% | 6.48% | 2.69% | 7.9% | 7.77% | 7.86% | 7.45% |
| Earnings before Tax (EBT) 1 | 396 | 224.7 | -34.41 | 493.8 | 443.4 | 288.6 | 189 | 679.4 | 547.3 | 363.7 | 165.4 | 509.5 | 553.8 | 553.8 | 598.1 |
| Net income 1 | 305.1 | 172.7 | -27.1 | 384.2 | 330 | 209.1 | 112.5 | 496.8 | 420.7 | 256.9 | 97.33 | 470 | 401.1 | 401.1 | 433.2 |
| Net margin | 7.64% | 4.02% | -0.62% | 8.22% | 6.54% | 4.1% | 1.75% | 8.35% | 6.96% | 4.48% | 1.44% | 6.87% | 5.63% | 5.43% | 5.06% |
| EPS 2 | 0.2708 | 0.1597 | -0.0347 | 0.3403 | 0.2848 | 0.1833 | 0.1000 | 0.4333 | 0.3767 | 0.2200 | 0.0985 | 0.3159 | 0.3029 | 0.3075 | 0.4462 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | 0.5906 | - | - |
| Announcement Date | 21-08-29 | 21-10-27 | 22-04-27 | 22-04-27 | 22-08-29 | 22-10-27 | 23-04-27 | 23-04-27 | 23-08-29 | 23-10-30 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,387 | 2,351 | 469 | 1,352 | 1,368 | 1,721 | 2,183 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 1,214 | 1,174 | 282 | 2,759 | 2,683 | 2,209 | 2,607 |
| ROE (net income / shareholders' equity) | 18.5% | 20.4% | 22.7% | 14.6% | 17.9% | 19.5% | 21% | 22.1% |
| ROA (Net income/ Total Assets) | 7.75% | 9.24% | 10.1% | 5.33% | 5.43% | 6.2% | 6.83% | 7.03% |
| Assets 1 | 6,860 | 7,605 | 10,502 | 14,834 | 19,088 | 21,024 | 23,833 | 28,083 |
| Book Value Per Share 2 | 2.820 | 3.790 | 4.560 | 4.640 | 5.290 | 6.090 | 7.090 | 8.110 |
| Cash Flow per Share 2 | 0.8100 | 1.530 | 1.720 | 1.370 | 3.300 | 2.190 | 2.320 | 2.820 |
| Capex 1 | 549 | 494 | 780 | 1,273 | 997 | 876 | 908 | 1,291 |
| Capex / Sales | 6.2% | 4.43% | 5.35% | 7.6% | 4.69% | 3.55% | 2.97% | 3.46% |
| Announcement Date | 19-03-04 | 20-04-28 | 21-04-19 | 22-04-27 | 23-04-27 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
21.2
CNY
Average target price
33.62
CNY
Spread / Average Target
+58.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.86% | 3.33B | |
| -32.21% | 15.27B | |
| -31.97% | 10.84B | |
| -30.42% | 6.06B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -6.93% | 3.01B |
- Stock Market
- Equities
- 603233 Stock
- Financials DaShenLin Pharmaceutical Group Co., Ltd.
